These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

777 related items for PubMed ID: 9417523

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Platelet transfusions irradiated with ultraviolet-B light may have a role in reducing recipient alloimmunization.
    Tandy NP, Pamphilon DH.
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):383-8. PubMed ID: 1893070
    [Abstract] [Full Text] [Related]

  • 23. Management of patients refractory to platelet transfusion.
    Chockalingam P, Sacher RA.
    J Infus Nurs; 2007 Apr; 30(4):220-5. PubMed ID: 17667077
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. D+ platelet transfusions in D- patients: cause for concern?
    Bartley AN, Carpenter JB, Berg MP.
    Immunohematology; 2009 Apr; 25(1):5-8. PubMed ID: 19856725
    [Abstract] [Full Text] [Related]

  • 27. The challenge of platelet alloimmunization: management and prevention.
    Kickler TS.
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Heterogeneity of antibody response to human platelet transfusion.
    Wu KK, Thompson JS, Koepke JA, Hoak JC, Flink R.
    J Clin Invest; 1976 Aug; 58(2):432-8. PubMed ID: 956376
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Minor impact of patient alloantibodies against human platelet antigen (HPA)-15 in the effectiveness of platelet transfusion: A pilot study.
    Inoue H, Sakamoto R, Nishimiya H, Sakamoto H, Terasu S, Aminaka R, Koh Y, Takihara Y, Hirayama F, Kuroishi A.
    Transfusion; 2021 Mar; 61(3):738-743. PubMed ID: 33166416
    [Abstract] [Full Text] [Related]

  • 32. Current status of leukocyte and platelet administration in cancer therapy.
    Walker EM, Cannon A, Mitchum EN.
    Ann Clin Lab Sci; 1983 Mar; 13(6):453-73. PubMed ID: 6197928
    [Abstract] [Full Text] [Related]

  • 33. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.
    Slichter SJ, Bolgiano D, Kao KJ, Kickler TS, McFarland J, McCullough J, Woodson R.
    Transfus Med Rev; 2011 Apr; 25(2):102-10. PubMed ID: 21345638
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model.
    Slichter SJ, Fish D, Abrams VK, Gaur L, Nelson K, Bolgiano D.
    Blood; 2005 Jan 15; 105(2):847-54. PubMed ID: 15231575
    [Abstract] [Full Text] [Related]

  • 36. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.
    Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A, Fackler-Schwalbe I, Fischer J, Gäckle R, Geer T, Harms P, Löffler B, Ohl S, Otremba B, Raab M, Schönrock-Nabulsi P, Strobel G, Winter R, Link H.
    Blood; 1998 May 15; 91(10):3601-6. PubMed ID: 9572994
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.